X4 Pharmaceuticals
XFOR
42 hedge funds and large institutions have $55.3M invested in X4 Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 20 closing their positions.
1,403% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $73K
937% more capital invested
Capital invested by funds: $5.33M → $55.3M (+$49.9M)
23.54% more ownership
Funds ownership: 48.44% → 71.98% (+24%)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
18% less funds holding
Funds holding: 51 → 42 (-9)
45% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$5.76M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.75M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$4.83M |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.47M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$302K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$252K |
| 3 |
Jane Street
New York
|
-$185K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$157K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$152K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
51
Schonfeld Strategic Advisors
New York
| – | -$21.4K | -11,261 | Closed |
|
|
HF
52
HRT Financial
New York
| – | -$20K | -10,548 | Closed |
|
53
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$5K | -2,414 | Closed |
|
54
Fidelity Investments
Boston,
Massachusetts
| – | -$3.22K | -1,697 | Closed |
|
|
AAP
55
Arax Advisory Partners
Denver,
Colorado
| – | -$2.13K | -1,120 | Closed |
|
56
Wells Fargo
San Francisco,
California
| – | -$661 | -348 | Closed |
|
57
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$283 | -149 | Closed |
|
58
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$264 | -139 | Closed |
|
59
Raymond James Financial
St Petersburg,
Florida
| – | -$125 | -66 | Closed |
|
|
CA
60
Clearstead Advisors
Cleveland,
Ohio
| – | -$122 | -64 | Closed |
|
|
EWA
61
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$44 | -23 | Closed |
|
|
TWD
62
True Wealth Design
Akron,
Ohio
| – | -$6 | -3 | Closed |
|
XFOR Hedge Fund Activity: Q3 2025 in Review
42 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2025, worth a combined $55.3M — up 937% from $5.33M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of XFOR and 11 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $5.76M. The largest seller was BlackRock, cutting an estimated $302K.
- 42 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2025, down from 51 in Q2 2025.
- Funds reported $55.3M of X4 Pharmaceuticals stock for Q3 2025, up 937% quarter-over-quarter.
- 11 funds opened new X4 Pharmaceuticals positions in Q3 2025 and 20 closed out, a net change of -9 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2025 was BVF Inc, an estimated $5.76M added.
- The largest X4 Pharmaceuticals seller in Q3 2025 was BlackRock, an estimated $302K sold.
Based on aggregated 13F filings for Q3 2025.